Company attributes
Funding Round attributes
Other attributes
Bit.bio is a supplier of in-vitro cell types for academic research and development and commercial drug discoveries. The company currently markets a range of cells and disease models for research and drug discovery including nerve cells, immune cells, and muscle cells. Bit.bio was founded by Mark Kotter in 2016 when it spun out of the University of Cambridge.
The company creates alternatives to cell resources such as primary cells in order to replace animal studies. The company looks to code cells to advance biological options for human treatments and create a platform that offers consistent cells for therapeutic drugs to treat cell and tissue issues.
Bit.bio is interested in providing synthetic and stem cell biology for biology circuits and biomanufacturing. Their primary application is to reprogram stem cells including in functional skeletal muscles. They work with human-induced glutamatergic neurons and human-induced skeletal myocytes. Through their technologies, they expect to be able to reproduce every human cell type. They believe the technology can stop the spread of pathogens.
